[go: up one dir, main page]

SE0203687D0 - Pharmaceutical Porous Particles - Google Patents

Pharmaceutical Porous Particles

Info

Publication number
SE0203687D0
SE0203687D0 SE0203687A SE0203687A SE0203687D0 SE 0203687 D0 SE0203687 D0 SE 0203687D0 SE 0203687 A SE0203687 A SE 0203687A SE 0203687 A SE0203687 A SE 0203687A SE 0203687 D0 SE0203687 D0 SE 0203687D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical
porous particles
sup
particle
porous
Prior art date
Application number
SE0203687A
Other languages
English (en)
Inventor
Ian Harwigsson
Original Assignee
Ian Harwigsson Med Adagit Fa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ian Harwigsson Med Adagit Fa filed Critical Ian Harwigsson Med Adagit Fa
Priority to SE0203687A priority Critical patent/SE0203687D0/sv
Publication of SE0203687D0 publication Critical patent/SE0203687D0/sv
Priority to AU2003287132A priority patent/AU2003287132B2/en
Priority to CA002509216A priority patent/CA2509216A1/en
Priority to EP03781201A priority patent/EP1569626A1/en
Priority to JP2005508295A priority patent/JP2006511617A/ja
Priority to PCT/SE2003/001952 priority patent/WO2004054556A1/en
Priority to US11/149,927 priority patent/US20060002995A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0203687A 2002-12-13 2002-12-13 Pharmaceutical Porous Particles SE0203687D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0203687A SE0203687D0 (sv) 2002-12-13 2002-12-13 Pharmaceutical Porous Particles
AU2003287132A AU2003287132B2 (en) 2002-12-13 2003-12-15 Pharmaceutical porous particles
CA002509216A CA2509216A1 (en) 2002-12-13 2003-12-15 Pharmaceutical porous particles
EP03781201A EP1569626A1 (en) 2002-12-13 2003-12-15 Pharmaceutical porous particles
JP2005508295A JP2006511617A (ja) 2002-12-13 2003-12-15 製薬用多孔質粒子
PCT/SE2003/001952 WO2004054556A1 (en) 2002-12-13 2003-12-15 Pharmaceutical porous particles
US11/149,927 US20060002995A1 (en) 2002-12-13 2005-06-10 Pharmaceutical porous particles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203687A SE0203687D0 (sv) 2002-12-13 2002-12-13 Pharmaceutical Porous Particles

Publications (1)

Publication Number Publication Date
SE0203687D0 true SE0203687D0 (sv) 2002-12-13

Family

ID=20289848

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203687A SE0203687D0 (sv) 2002-12-13 2002-12-13 Pharmaceutical Porous Particles

Country Status (2)

Country Link
US (1) US20060002995A1 (sv)
SE (1) SE0203687D0 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006028916B4 (de) * 2006-06-23 2015-07-16 Robert Bosch Gmbh Verfahren zur Herstellung poröser Partikel
MX2011011134A (es) * 2009-04-21 2012-01-31 Selecta Biosciences Inc Agentes inmunonanoterapeuticos que proporcionan una respuesta sesgada hacia th1.
MX2011012599A (es) * 2009-05-27 2012-04-19 Selecta Biosciences Inc Compuestos polimericos de agentes inmunomoduladores.
MX352324B (es) 2010-05-26 2017-11-17 Selecta Biosciences Inc Star Vacunas multivalentes de nanovehiculos sinteticos.
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
DK3104853T3 (da) 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation

Also Published As

Publication number Publication date
US20060002995A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
SE0203687D0 (sv) Pharmaceutical Porous Particles
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
EA200300834A1 (ru) Антагонисты фактора, высвобождающего кортикотропин
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
CY1106420T1 (el) Νανοσωματιδιακα σκευασματα ινσουλινης
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
NO20023313L (no) Nye substituerte benzimidazol doseringsformer og fremgangsmåte for anvendelse av samme
HRP20030951B1 (hr) Formulacije jednodnevnih doza oksikodona
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
DK1102579T3 (da) Medicinske aerosolformuleringer
DK1372608T3 (da) Medicinske aerosolformuleringer
JP2005526147A5 (sv)
DE602004007257D1 (de) Hydroxy-diaryl-carbaldehyd- oxim-verbindungen und deren verwendung als oestrogenwirksame substanzen
JP2004515500A5 (sv)
UY27760A1 (es) Nuevos derivados de pirrolidinio.
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
SE0100822D0 (sv) Method II to obtain microparticles
YU17301A (sh) KRISTALNI OBLICI EtO2C-CH2-(R)-Cgl-Aze-Pab-OH
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE339224T1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες